



10-2803

PATENT

11-6
11-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 11738.00038)

In the Application of:)
Hartlaub et al.) Group Art Unit: 3763
Serial No. 10/005,789) Examiner: Kathryn L. Thompson
Filed: November 8, 2001)
For: INFUSION SYSTEMS FOR CREATING)
MICROENVIRONMENTS IN A LIVING)
BODY)

RECEIVED
NOV 03 2003
TECHNOLOGY CENTER R3700

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, the Applicants wish to make the following references of record in the above-identified application and state that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. 1.56. Copies of the references cited below are enclosed. The references are also listed on the enclosed and completed PTO Form 1449.

This Information Disclosure Statement is being filed after receipt of a First Office Action. Accordingly, a fee of \$180.00 is required. The Commissioner is authorized to charge our Deposit Account No. 19-0733.

10/31/2003 SSITHIB1 00000102 190733
01 FC:1806 180.00 DA

REFERENCES

U.S. Patents

1. Masters, US. 2003/0007991 A1, published January 9, 2003;
2. Kühl et al., U.S. Patent No. 4,140,122, issued February 20, 1979;
3. Brown et al., U.S. Patent No. 4,952,406, issued August 28, 1990;
4. Aebischer et al., U.S. Patent No. 5,011,472, issued April 30, 1991;
5. Currie et al., U.S. Patent No. 5,366,454, issued November 22, 1994;
6. Seckel, U.S. Patent No. 5,584,885, issued December 17, 1996;
7. Hadden, U.S. Patent No. 5,632,983, issued May 27, 1997;
8. Rise, U.S. Patent No. 5,643,207, issued July 1, 1997;
9. Elsberry et al., U.S. Patent No. 5,711,316, issued January 27, 1998;
10. Kmiec, U.S. Patent No. 5,731,181, issued March 24, 1998;
11. Elsberry, U.S. Patent No. 5,735,814, issued April 7, 1998;
12. Medencia et al., U.S. Patent No. 5,736,129, issued April 7, 1998;
13. Otto, U.S. Patent No. 5,769,823, issued June 23, 1998;
14. Kmiec, U.S. Patent No. 5,795,972, issued August 18, 1998;
15. Elsberry et al., U.S. Patent No. 5,814,014, issued September 29, 1998;
16. Elsberry et al., U.S. Patent No. 5,832,932, issued November 10, 1998;
17. Weiss et al., U.S. Patent No. 5,980,885, issued November 9, 1999;
18. Kumar et al. U.S. Patent No. 6,004,804, issued December 21, 1999;
19. Kmiec et al., U.S. Patent No. 6,010,907, issued January 4, 2000;
20. Elsberry, U.S. Patent No. 6,042,579, issued March 28, 2000;
21. Elsberry, U.S. Patent No. 6,093,180, issued July 25, 2000;
22. Soykan et al., U.S. Patent No. 6,151,525 issued November 21, 2000; and
23. Soykan et al., U.S. Patent No. 6,206,914 issued March 27, 2001.

Foreign Patents

1. Elsberry et al., PCT Publication No. WO 97/40874, issued November 6, 1997;
2. Stokes et al., PCT Publication No. WO 98/02040, issued January 22, 1998;
3. Stokes et al., PCT Publication No. WO 98/02150, issued January 22, 1998;
4. Haynes et al., PCT Publication No. WO 98/15615, issued April 16, 1998;
5. Elsberry et al., PCT Publication No. WO 98/48723, issued November 5, 1998.

Other References

BANNER & WITCOFF, LTD.
10 South Wacker Drive
Suite 3000
Chicago, Illinois 60606
Telephone: (312) 715-1000
Facsimile: (312) 715-1234

- 1 Metzler, M., Helgason, C., Dragatsis, I., Zhang, T., Gan, L., Pineult, N., Zeitlin, S., Humphries, R., and Hayden, M., "Huntington is required for normal hematopoiesis," *Hum. Mol. Genet.* 9: 387-94 (2000)
2. Kren, B., Cole-Strauss, A., Kmiec, E., and Steer, C., "Targeted nucleotide exchange in the alkaline phosphatase gene of HuH-7 cells mediated by a chimeric RNA/DNA oligonucleotide," *Hepatology* 25: 1462-8 (1997)
3. Kren, B., Bandyopadhyay, P., and Steer, C., "In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides," *Nature Medicine* 4: 285-90 (1998)
4. Kren, B., Parashar, B., Bandyopadhyay, P., Chowdhury, N., Chowdhury, J., and Steer, C., "Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide," *Proc. Natl. Acad. Sci. USA* 96: 10349-54 (1999)
5. Bandyopadhyay, P., Ma, X., Linehan-Stieers, C., Kren, B., and Steer, C., "Nucleotide exchange in genomic DNA of rat hepatocytes using RNA/DNA oligonucleotides- Targeted delivery of liposomes and polyethylenimine to the asialoglycoprotein receptor," *J. Biol. Chem.* 274: 10163-72 (1999)
6. Havre, P. and Kmiec, E. (1998) RecA-mediated joint molecule formation between O-methylated RNA/DNA hairpins and single-stranded targets. *Mol Gen Genet* 258 (6): 580-586
7. Gamper, H.J., Cole-Strauss, A., Metz, R., Parekh, H., Kumar, R. and Kmiec, E. (2000) A plausible mechanism for gene correction by chimeric oligonucleotides. *Biochemistry* 39 (19): 5808-5816
8. Cole-Strauss, A., Gamper, H., Holloman, W., Munoz, M., Cheng, N. and Kmiec, E. (1999) Targeted gene repair directed by the chimeric RNA/DNA oligonucleotide in a mammalian cell-free extract. *Nucleic Acids Research* 27 (5): 1323-1330
9. Klement, I., Skinner, P., Kaytor, M., Yi, H., Hersch, S., Clark, H., Zoghbi, H. and Orr, H. (1998) Ataxin-1 Nuclear Localization and Aggregation: Role in Polyglutamine-Induced Disease in SCA1 Transgenic Mice, *Cell*, Vol. 95, pg. 41-53, 10/2/98.

10. Ellerby, L., Andrusiak, R., Wellington, C., Hackam, A., Propp, S., Wood, J., Sharp, A., Margolis, R., Ross, C., Salvesen, G., Hayden, M. and Bredesen, D. (1999) Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. *J Biol Chem* 274 (13): 8730-8736
11. Faber, P., Alter, J., MacDonald, M. and Hart, A. (1999) Polyglutamine-mediated dysfunction and apoptotic death of a *caenorhabditis elegans* sensory neuron. *Proc Natl Acad Sci USA* 96 (1): 179-184
12. Prospects of Chimeric RNA-DNA Oligonucleotides in Gene Therapy, Xue-Song Wu, De-Pei Liu Chih-Chuan Liang, National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PRC; *Journal of Biomedical Science*, 2001 8:439-445.
13. Targeted Gene Repair and Its Application to Neurodegenerative Disorders, Hetal Parekh-Olmedo, et al., Department of Biological Sciences Delaware Biotechnology Institute University of Delaware Newark, Department of Neurology Massachusetts General Hospital Harvard Medical School Boxton MA, *Neuron*, Vol. 33, 495-498, February 14, 2002.
14. Recombinant Proteins for Neurodegenerative Diseases: The Delivery Issue, Patrick Aebsicher et al., *Trends in Nerosciences* Vol. 24, No. 9 September 2001.
15. Whittemore et al, Gene Therapy and the Use of Stem Cells for Central Nervous System Regeneration, *Advances in Neurology* Vol 72, pp. 113-119 (1997).
16. Will, et al. "Regeneration in Brain and Spinal Cord", Cellular and Molecular Basis of Regeneration From Invertebrates to Humans", pp. 379-397, Willey & Sons (1998).
17. Stitchel-Gunkel, "The Role of the Microenvironment in Axonal Regeneration," *Advances in Anatomy, Embryology and Cell Biology* 137 (1997).
18. Gorio, Neuroregeneration, deVellis, "Supporting Cells Central and Peripheral", Chapter 4, pp. 61-62 (1992).
19. Berry and Logan, CNS INJURIES: Cellular Responses and Pharmacological Strategies, Chapter 9, pp. 169-189 (1998).

20. Seil, M.D., "Neuronal Regeneration, Reorganization, and Repair," Advances in Neurology, Vol. 72, pp. 121-123 (1997).

Respectfully submitted,

BANNER & WITCOFF, LTD

Dated: October 27, 2003

By:



Scott A. Burow
Reg. No. 42,373

BANNER & WITCOFF, LTD.
10 South Wacker Drive
Suite 3000
Chicago, Illinois 60606
Telephone: (312) 715-1000
Facsimile: (312) 715-1234



RECEIVED

NOV 03 2003

CERTIFICATE OF MAILING
(PATENT APPLICATION)

Express Mail No. EL941345632US

TECHNOLOGY CENTER R3700

Deposited: October 27, 2003

I hereby certify that the attached correspondence, identified below, is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

By:

Application of: Hartlaub

Application No.: 10/005,789

Filing Date: November 8, 2001

Title: Infusion System for Creating Microenvironments in a Living Body

Transmitted herewith are the following documents:

- Fee Transmittal Form (1 page) in duplicate
- Transmittal Form (1 page) in duplicate
- Information Disclosure Statement (5 pages)
- PTO SB/08A (2 pages) with cited references attached
- Return Postcard

Attorney Case No.: 11738.00038

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

OCT 27 2003

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Application Number

10/005,789

Filing Date

November 8, 2001

First Named Inventor

Hartlaub

Art Unit

3763

Examiner Name

Kathryn L. Thompson

Total Number of Pages in This Submission

Attorney Docket Number

11738.00038

RECEIVED
NOV 03 2003
TECHNOLOGY CENTER R3700

ENCLOSURES (check all that apply)

 Fee Transmittal Form Fee Attached Amendment / Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 Assignment Papers
(for an Application) Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) _____ After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s)
(please identify below):


PTO SB/08A with cited references attached.

Remarks

Being filed via Express Mail No.:EL941345632US

The Commissioner is hereby authorized to charge any deficiencies in payment or credit any overpayment to our Deposit Account 19-0733.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Scott A. Burow	
Signature		
Date	October 27, 2003	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name		
Signature		Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEES TRANSMITTAL
for FY 2004**

OCT 27 2003
Effective 10/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT	(\$ 180)
-------------------------	----------

*RECEIVED
NOV 03 2003
TECHNOLOGY CENTER A3700*

METHOD OF PAYMENT (check all that apply)				FEE CALCULATION (continued)			
<input type="checkbox"/> Check <input type="checkbox"/> Credit card <input type="checkbox"/> Money <input type="checkbox"/> Other <input type="checkbox"/> None <input checked="" type="checkbox"/> Deposit Account				3. ADDITIONAL FEES			
Deposit Account Number	19-0733			Large Entity	Small Entity		
Deposit Account Name	Banner & Witcoff, LTD.			Fee Code	Fee (\$)	Fee Code	Fee (\$)
The Director is authorized to: (check all that apply)				Fee Description			
<input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments <input type="checkbox"/> Charge any additional fee(s) during the pendency of this application <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.				Fee Paid			
FEE CALCULATION				Fee Description			
1. BASIC FILING FEE				Fee Paid			
Large Entity	Fee Description			Fee Code	Fee (\$)	Fee Code	Fee (\$)
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid	Fee Code	Fee (\$)
1001	770	2001	385	Utility filing fee	(1)	2051	65
1002	340	2002	170	Design filing fee	(2)	2052	25
1003	530	2003	265	Plant filing fee	(3)	1053	130
1004	770	2004	385	Reissue filing fee	(4)	1812	2,520
1005	160	2005	80	Provisional filing fee	(5)	1804	920*
SUBTOTAL (1)				(\$ 0)			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE				Fee Paid			
Total Claims	Extra Claims	Fee from below	Fee Paid	Fee Code	Fee (\$)	Fee Code	Fee (\$)
Independent Claims	- ** = 0	X _____	= 0	1255	2,010	2255	1,005
Multiple Dependent	- ** = 0	X _____	= 0	1401	330	2401	165
X _____	= 0	X _____	= 0	1402	330	2402	165
SUBTOTAL (2)				(\$ 0)			
Other fee (specify) _____				SUBTOTAL (3) (\$ 180)			
*Reduced by Basic Filing Fee Paid				SUBTOTAL (3) (\$ 180)			

**or number previously paid, if greater; For Reissues, see above

SUBMITTED BY			Complete (if applicable)		
Name (Print/Type)	Scott A. Burow	Registration No. (Attorney/Agent)	42,373	Telephone	312-463-5000
Signature	<i>Scott A. Burow</i>			Date	October 27, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.